Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Abstract Background Sintilimab blocks the interaction between programmed death-1 (PD-1) and its ligands. The safety and efficacy of sintilimab combined with oxaliplatin/capecitabine (CapeOx) as first-line treatment were evaluated in patients with gastric (G)/gastroesophageal junction (GEJ) adenocarc...

Full description

Bibliographic Details
Main Authors: Haiping Jiang, Yulong Zheng, Jiong Qian, Chenyu Mao, Xin Xu, Ning Li, Cheng Xiao, Huan Wang, Lisong Teng, Hui Zhou, Shuyan Wang, Donglei Zhu, Bo Peng, Lin Shen, Nong Xu
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Cancer
Subjects:
Sintilimab
Capecitabine
Oxaliplatin
Gastric/gastroesophageal junction adenocarcinoma
Tumor mutation burden
Online Access:http://link.springer.com/article/10.1186/s12885-020-07251-z

Internet

http://link.springer.com/article/10.1186/s12885-020-07251-z

Similar Items